Skip to main content
Premium Trial:

Request an Annual Quote

Seegene, Samsung Enter Cancer MDx Pact

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Seegene and Samsung Medical Center today said they will collaborate to develop new molecular diagnostics tests directed at cancer.

The partnership combines Seegene's MDx technology with Samsung's clinical and disease pathology expertise, the two firms said. They added that Samsung will provide the first test sites for the diagnostic products.

The tests will be based on Seegene's multiplex PCR and real-time PCR technology to detect genetic mutations suggestive of certain cancers. Initial indications of interest are non-small-cell lung cancer, colon cancer, pancreatic cancer, and cholangiocarcinoma.

According to the firms, the deal launches Seegene into the personalized medicine space, and as part of the deal, the South Korean firm, which went public in September, will develop new tests for drug resistance and to test for single nucleotide polymorphisms.

Clinicians will be able to use tests to profile patients to understand how they are likely to respond to cancer therapies and whether the cancer will return or has metastasized, the companies said.

Financial and other terms of the deal were not disclosed.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.